

Datasheet: PHP030A

Description:	RECOMBINANT HUMAN EGF
Name:	EGF
Other names:	EPIDERMAL GROWTH FACTOR
Format:	Rec. Protein
Product Type:	Recombinant Protein
Quantity:	0.5 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	•			0.2 - 0.4ng/well
Western Blotting	•			1.5 - 3.0ng/lane
Functional Assays	•			0.5 - 25ng/ml

Where this protein has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the protein for use in their own system using appropriate postive/negative controls.

Target Species	Human
Species Cross	Reacts with: Mouse
Reactivity	N.B. Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.
Product Form	Purified recombinant protein - lyophilized
Reconstitution	Reconstitute with 0.5ml distilled water
	Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. For extended storage, the addition of 5% trehalose is recommended
Preparation	Purified recombinant human EGF expressed in <i>E. coli</i>
Source	E.coli

Preservative Stabilisers	None present
Carrier Free	Yes
Endotoxin Level	< 0.1 ng/ug
Approx. Protein Concentrations	1.0 mg/ml after reconstitution.
External Database Links	UniProt: P01133 Related reagents
	Entrez Gene: 1950 EGF Related reagents
Product Information	Recombinant human epidermal growth factor is 6.2kDa globular protein comprosed of 53 amino acids. EGF is a polypeptide growth factor which stimulates the proliferation of a wide range of epidermal and epithelial cells.
Protein Molecular Weight	6.2 kD (53 Amino acid sequence)
Activity	1 x 10 ⁷ units/mg
Purity	>98% by SDS PAGE and HPLC analysis
ELISA	Recombinant human EGF may be used as athe standard in ELISA applications with either a <u>purified human EGF antibody</u> (AHP767) or a <u>biotinylated human EGF antibody</u> (AHP767B).
Western Blotting	Recombinant human EGF may be used as the positive control for Wester Blotting application with either a <u>purified human EGF antibody</u> (AHP767) or a <u>biotinylated human EGF antibody</u> (AHP767B)
References	 Tomlins, C. & Storey, A. (2010) Cutaneous HPV5 E6 causes increased expression of Osteoprotegerin and Interleukin 6 which contribute to evasion of UV-induced apoptosis. Carcinogenesis. 31 (12): 2155-64. Wray, H. et al. (2012) α6 Integrin and CD44 enrich for a primary keratinocyte population that displays resistance to UV-induced apoptosis. PLoS One. 7 (10): e46968. Chen, W. et al. (2016) Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases. PLoS One. 11 (11): e0166268. Zhang, X. et al. (2015) Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells. Med Oncol. 32 (4): 95. Roth, K. et al. (2021) Clinically relevant aberrant Filip1I DNA methylation detected in a murine model of cutaneous squamous cell carcinoma. EBioMedicine. 67: 103383.

- 6. Inman, G.J. *et al.* (2018) The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. <u>Nat Commun. 9 (1): 3667.</u>
- 7. Aiderus, A. *et al.* (2021) Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression. <u>PLoS Genet. 17 (8): e1009094.</u>
- 8. Scemama, A. *et al.* (2023) Development of an *in vitro* microfluidic model to study the role of microenvironmental cells in oral cancer metastasis F1000Research. 12: 439.
- 9. Zhang, Y. *et al.* (2020) Sulfoxythiocarbamate S-4 inhibits HSP90 in human cutaneous squamous cell carcinoma cells. <u>Eur J Pharmacol. 889: 173609.</u>

Storage

Prior to reconstitution store at -20°C. Following reconstitution store at -20°C if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee

Guaranteed for 3 months from the date of reconstitution or until the date of expiry,

whichever comes first. Please see label for expiry date.

Health And Safety Information

Material Safety Datasheet documentation #10527 available at:

https://www.bio-rad-antibodies.com/SDS/PHP030A

10527

Regulatory

For research purposes only

 North & South
 Tel: +1 800 265 7376
 Worldwide
 Tel: +44 (0)1865 852 700
 Europe
 Tel: +49 (0) 89 8090 95 21

 America
 Fax: +1 919 878 3751
 Fax: +44 (0)1865 852 739
 Fax: +49 (0) 89 8090 95 50

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M433621:241118'

Printed on 18 Nov 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint